Your session is about to expire
← Back to Search
Epcoritamab +/- Lenalidomide for Non-Hodgkin's Lymphoma (EPCORE DLBCL-3 Trial)
EPCORE DLBCL-3 Trial Summary
This trial will test a new antibody and a drug for elderly patients with DLBCL who can't take other medicines. All patients will get active treatment.
EPCORE DLBCL-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEPCORE DLBCL-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EPCORE DLBCL-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is at stage II, III, or IV according to the Ann Arbor classification.I have been treated with specific therapies recently.I have or had cancer types other than the one I'm seeking treatment for.I have seizures and need medication for it, or I've had a seizure in the last 6 months.My recent blood tests show my organs are functioning well.I might have active or untreated latent tuberculosis.I am currently being treated for an active CMV infection.I do not have any significant infections, including COVID-19, at the time of joining the trial.My cancer has spread to my brain.I can care for myself but may not be able to do heavy physical work.I am over 75 with health issues or over 80, making me ineligible for certain cancer treatments.I have been recently diagnosed with a type of lymphoma that tests positive for CD20.I have a severe heart condition.I have hepatitis B or C, current alcohol abuse issues, or cirrhosis.
- Group 1: Epcoritamab monotherapy
- Group 2: Epcoritamab in combination with lenalidomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues are actively engaging in this experiment?
"There are 36 medical sites partaking in this research project, including GZA Ziekenhuizen in Antwerp, Institut Jules Bordet in Brussel, and Universitair Ziekenhuis Brussel located nearby Leuven. Additionally, there are several other locales involved as well."
Is the enrollment period for this research study still open?
"Per the data present on clinicaltrials.gov, this research project is currently recruiting participants. It was first listed on March 1st 2023 and has received an update as recently as March 3rd of the same year."
Has the FDA greenlit Epcoritamab as a solo treatment option?
"With Phase 2 data supporting its safety, our team at Power assigned Epcoritamab monotherapy a score of 2. Unfortunately, there is no evidence demonstrating efficacy yet."
How many participants are participating in this medical study?
"Affirmative. According to clinicaltrials.gov, this medical experiment posted on March 1st 2023 and recently updated on the 3rd of March is actively recruiting patients for participation. 180 individuals are being sought from 36 different institutions."
Share this study with friends
Copy Link
Messenger